B7-H3.CD28Z.CART therapy (Dana-Farber)

N/A

Report date: 2026/05/14 20:00:28

Base Information

Drug NameB7-H3.CD28Z.CART therapy (Dana-Farber)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsCD276 antigen modulatorsT-cell-specific surface glycoprotein CD28 modulators
TargetsCD276 antigenT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsSolid tumoursNeuroblastoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe Band Of ParentsDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteThe Band Of Parents
Inactive CompaniesN/A
Active IndicationsSolid tumoursNeuroblastoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A